Cargando…

Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma

m6A RNA methylation regulators can regulate the growth, progression, and invasion of glioma cells by regulating their target genes, which provides a reliable support for the m6A regulator–target axes as the novel therapeutic targets and clinical prognostic signature in glioma. This study aimed to ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Cong, Peilin, Wu, Tingmei, Huang, Xinwei, Liang, Huazheng, Gao, Xiaofei, Tian, Li, Li, Wanrong, Chen, Aiwen, Wan, Hanxi, He, Mengfan, Dai, Danqing, Li, Zhen, Xiong, Lize
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473691/
https://www.ncbi.nlm.nih.gov/pubmed/34589481
http://dx.doi.org/10.3389/fcell.2021.709022
_version_ 1784575046060081152
author Cong, Peilin
Wu, Tingmei
Huang, Xinwei
Liang, Huazheng
Gao, Xiaofei
Tian, Li
Li, Wanrong
Chen, Aiwen
Wan, Hanxi
He, Mengfan
Dai, Danqing
Li, Zhen
Xiong, Lize
author_facet Cong, Peilin
Wu, Tingmei
Huang, Xinwei
Liang, Huazheng
Gao, Xiaofei
Tian, Li
Li, Wanrong
Chen, Aiwen
Wan, Hanxi
He, Mengfan
Dai, Danqing
Li, Zhen
Xiong, Lize
author_sort Cong, Peilin
collection PubMed
description m6A RNA methylation regulators can regulate the growth, progression, and invasion of glioma cells by regulating their target genes, which provides a reliable support for the m6A regulator–target axes as the novel therapeutic targets and clinical prognostic signature in glioma. This study aimed to explore the role and prognostic value of m6A RNA methylation regulators and their targets. Expression profiles and clinicopathological data were obtained from the Chinese Glioma Genome Atlas (CGGA), The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Clinical Proteome Tumor Analysis Consortium (CPTAC) datasets. Differential expression and correlation analyses were performed between normal and glioma tissues at mRNA and protein levels. Univariate Cox regression, survival, and Lasso Cox regression analyses were conducted to identify and establish the prognostic gene signature. Kaplan–Meier curve, multivariate Cox regression analysis, and ROC were utilized to evaluate the prognostic capacity of the prognostic gene signature. The correlation analysis, systematic bioinformatics analysis, and cell experiment were performed to further understand the potential underlying molecular mechanisms and drug sensitivity. Our results suggested that IGF2BP2, KIAA1429, METTL16, and METTL3, as well as 208 targets are involved in the occurrence of glioma, GBM, and LGG. YTHDF1 and 78 targets involved the occurrence of glioma and GBM, not LGG, among which 181 genes were associated with overall survival. From other findings and our cell experiment results, we demonstrated that METTL3 can activate Notch pathway and facilitate glioma occurrence through regulating its direct targets NOTCH3, DLL3, and HES1, and Notch pathway genes may serve as the potential treatment targets for glioma. Our study established and validated a seven-gene signature comprising METTL3, COL18A1, NASP, PHLPP2, TIMP1, U2AF2, and VEGFA, with a good capability for predicting glioma survival, which may guide therapeutic customization and clinical decision-making. These genes were identified to influence 81 anticancer drug responses, which further contributes to the early phase clinical trials of drug development.
format Online
Article
Text
id pubmed-8473691
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84736912021-09-28 Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma Cong, Peilin Wu, Tingmei Huang, Xinwei Liang, Huazheng Gao, Xiaofei Tian, Li Li, Wanrong Chen, Aiwen Wan, Hanxi He, Mengfan Dai, Danqing Li, Zhen Xiong, Lize Front Cell Dev Biol Cell and Developmental Biology m6A RNA methylation regulators can regulate the growth, progression, and invasion of glioma cells by regulating their target genes, which provides a reliable support for the m6A regulator–target axes as the novel therapeutic targets and clinical prognostic signature in glioma. This study aimed to explore the role and prognostic value of m6A RNA methylation regulators and their targets. Expression profiles and clinicopathological data were obtained from the Chinese Glioma Genome Atlas (CGGA), The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Clinical Proteome Tumor Analysis Consortium (CPTAC) datasets. Differential expression and correlation analyses were performed between normal and glioma tissues at mRNA and protein levels. Univariate Cox regression, survival, and Lasso Cox regression analyses were conducted to identify and establish the prognostic gene signature. Kaplan–Meier curve, multivariate Cox regression analysis, and ROC were utilized to evaluate the prognostic capacity of the prognostic gene signature. The correlation analysis, systematic bioinformatics analysis, and cell experiment were performed to further understand the potential underlying molecular mechanisms and drug sensitivity. Our results suggested that IGF2BP2, KIAA1429, METTL16, and METTL3, as well as 208 targets are involved in the occurrence of glioma, GBM, and LGG. YTHDF1 and 78 targets involved the occurrence of glioma and GBM, not LGG, among which 181 genes were associated with overall survival. From other findings and our cell experiment results, we demonstrated that METTL3 can activate Notch pathway and facilitate glioma occurrence through regulating its direct targets NOTCH3, DLL3, and HES1, and Notch pathway genes may serve as the potential treatment targets for glioma. Our study established and validated a seven-gene signature comprising METTL3, COL18A1, NASP, PHLPP2, TIMP1, U2AF2, and VEGFA, with a good capability for predicting glioma survival, which may guide therapeutic customization and clinical decision-making. These genes were identified to influence 81 anticancer drug responses, which further contributes to the early phase clinical trials of drug development. Frontiers Media S.A. 2021-09-13 /pmc/articles/PMC8473691/ /pubmed/34589481 http://dx.doi.org/10.3389/fcell.2021.709022 Text en Copyright © 2021 Cong, Wu, Huang, Liang, Gao, Tian, Li, Chen, Wan, He, Dai, Li and Xiong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Cong, Peilin
Wu, Tingmei
Huang, Xinwei
Liang, Huazheng
Gao, Xiaofei
Tian, Li
Li, Wanrong
Chen, Aiwen
Wan, Hanxi
He, Mengfan
Dai, Danqing
Li, Zhen
Xiong, Lize
Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma
title Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma
title_full Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma
title_fullStr Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma
title_full_unstemmed Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma
title_short Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma
title_sort identification of the role and clinical prognostic value of target genes of m6a rna methylation regulators in glioma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473691/
https://www.ncbi.nlm.nih.gov/pubmed/34589481
http://dx.doi.org/10.3389/fcell.2021.709022
work_keys_str_mv AT congpeilin identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT wutingmei identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT huangxinwei identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT lianghuazheng identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT gaoxiaofei identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT tianli identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT liwanrong identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT chenaiwen identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT wanhanxi identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT hemengfan identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT daidanqing identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT lizhen identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma
AT xionglize identificationoftheroleandclinicalprognosticvalueoftargetgenesofm6arnamethylationregulatorsinglioma